IP Library Granted Patent US 9,428,815
Granted Patent B2
US 9,428,815 · App. 12/595,358 · Granted Aug 30, 2016

HIV-1 reverse transcriptase codon deletion and its use in the management and treatment of HIV infections

Inventor: Raymond F. Schinazi (Atlanta, GA)
Assignee: Emory University
C12Q1/703C12N9/1276G06F19/18G06F19/28Y10S435/911
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,428,815
App. No.
12/595,358
Granted
Aug 30, 2016
Kind
B2
Abstract

The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided.

Claims (3)

1. A method of evaluating the effectiveness of an antiretroviral agent on inhibiting HIV replication of an HIV virus comprising a codon 68 deletion in the reverse transcriptase coding sequences, the method comprising the steps of: (i) treating cells with an antiretroviral agent; (ii) infecting cells with an HIV virus comprising a codon 68 deletion in the reverse transcriptase coding sequences, wherein the deletion results in an amino acid sequence change from DST at positions 67-69 to DT; and (iii) determining the effect of the agent on HIV RNA production; wherein steps (i) and (ii) may be performed in any order.

2. The method of claim 1 , wherein the antiretroviral agent is selected from the group consisting of DFC, lamivudine, emtricitabine, tenofovir, abacavir, and amdoxovir.

3. A method of evaluating the effectiveness of an antiretroviral agent on inhibiting HIV replication of an HIV virus comprising SEQ ID NO:7 in the reverse transcriptase coding sequences, the method comprising the steps of: (i) treating cells with an antiretroviral agent; (ii) infecting cells with an HIV virus comprising SEQ ID NO:7 in the reverse transcriptase coding sequences; and (iii) determining the effect of the agent on HIV RNA production; wherein steps (i) and (ii) may be performed in any order.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 25, 2011
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027281/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2010
From: SCHINAZI, RAYMOND F.
To: EMORY UNIVERSITY
Reel/Frame 023960/0804 →
Continuity (2)
Provisional Application 60922838 · Apr 10, 2007
Related Publication 20100130381A1 · May 27, 2010